Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

Germany's Merck agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. Domino's Pizza logged ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add ...

Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...